Clinical Pharmacometrics for Rational Drug Treatment
نویسندگان
چکیده
منابع مشابه
Pharmacometrics: Impacting Drug Development and Pharmacotherapy
Drug development continues to be expensive, time consuming, and ineffi cient, while pharmacotherapy is often practiced at suboptimal levels of performance (1–3). This trend has not waned despite the fact that massive amounts of drug data are obtained each year. Within these massive amounts of data, knowledge that would improve drug development and pharmacotherapy lays hidden and undiscovered. T...
متن کاملdrug consumption; rational choice model for addiction?
“rational choice model” is one of the economics theories which developed into sociology, politics, and anthropology and was applied to understand and justify some phenomena. according to this hypothesis, the basis of decision making is improvements, enjoyment and suffering disposal. people always do all necessary calculations in each and every decision making and then adopt a rational decision...
متن کاملPoly Drug Use - A Challenge for Drug Treatment
Poly-drug use refers to the use of two or more substances at the one time or repeatedly. It is common among both recreational and regular drug users across the world. Poly-drug use is a great contributor to the global number of deaths related to drug overdose. In this case, the likelihood of drug overdose and its pertaining complications in an individual is higher especially when benzodiazepine...
متن کاملPharmacometrics to improve clinical benefit assessment in oncology
Schindler, E. 2018. Pharmacometrics to improve clinical benefit assessment in oncology. Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 243. 73 pp. Uppsala: Acta Universitatis Upsaliensis. ISBN 978-91-513-0191-4. The high attrition rate in oncology drug development calls for new approaches that would increase the understanding of drugs’ efficacy and safety ...
متن کاملCommentary on Pharmacometrics for Immunotherapy
This commentary provides an overview of recent examples of pharmacometrics applied during the clinical development of two antagonists of the programmed death-1 (PD-1) cell surface receptor, pembrolizumab and nivolumab. Despite the remarkable achievements obtained in predicting the correct dosing schedule from different quantitative approaches, data indicated a great degree of heterogeneity in t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: YAKUGAKU ZASSHI
سال: 2019
ISSN: 0031-6903,1347-5231
DOI: 10.1248/yakushi.19-00124